The Role of Glomerular and Serum Expression of Lymphocyte Activating Factors BAFF and APRIL in Patient with Membranous and IgA Nephropathies
Archivum Immunologiae et Therapiae Experimentalis · 2025
DOI: 10.2478/aite-2025-0018 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Archivum Immunologiae et Therapiae Experimentalis, 2025. Verfasst von Barbara Moszczuk und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Immunology, Medical University of Warsaw, Warsaw, Poland. Hauptthemen laut MEDLINE: B-Cell Activating Factor, Tumor Necrosis Factor Ligand Superfamily Member 13, B-Lymphocytes, Glomerulonephritis, IGA. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Increased activity of B lymphocytes underpins many autoimmune conditions. A key component of the humoral immune response involves the A PRoliferation-Inducing Ligand (APRIL) and B-cell-activating factor (BAFF) system. These proteins are responsible for the activation, maturation, and survival of B lymphocytes, playing a pivotal role in autoimmunity. Therefore, targeting the BAFF/APRIL system proves promising for the treatment of various autoimmune diseases. Meticulous research into pathomechanisms of lupus nephritis (LN) has enabled the introduction of biological treatments targeting the BAFF-mediated pathway, significantly improving prognosis. In certain types of glomerulonephritis (GN), increased levels of the BAFF/APRIL system might be associated with higher proteinuria, elevated serum creatinine, but also with specific histopathological features. This indicates that biological therapies currently available could be repurposed for conditions where increased activation of B lymphocytes plays a critical role in the disease's pathophysiology. Understanding the mechanisms underlying autoimmune diseases will facilitate the adaptation of novel drugs for orphan diseases. That is why the use of chimeric antigen receptor T (CAR-T) cells as agents against B-cells receptor (BCR), represents a highly targeted and potentially optimal treatment approach. This study summarizes current knowledge about the role of the BAFF/APRIL system in lymphocyte activation mechanisms, particularly in GN. It also discusses existing biological treatments and explores future directions for drug development based on the CAR-T cell technology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Immunology, Medical University of Warsaw, Warsaw, Poland.
- Department of Transplantology, Immunology, Nephrology and Internal Diseases, Medical University of Warsaw, Warsaw, Poland.
- ProMix Center (ProteogenOmix in Medicine), Department of Clinical Immunology, Medical University of Warsaw, Warsaw, Poland.
- Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Warsaw, Poland.
- Laboratory of Cellular and Genetic Therapies, Center for Preclinical Research, Medical University of Warsaw, Warsaw, Poland.
Zitieren
APA
Moszczuk, B., Mucha, K., Kucharczyk, R., & Zagożdżon, R. (2025). The Role of Glomerular and Serum Expression of Lymphocyte Activating Factors BAFF and APRIL in Patient with Membranous and IgA Nephropathies. Archivum Immunologiae et Therapiae Experimentalis. https://doi.org/10.2478/aite-2025-0018
Vancouver
Moszczuk B, Mucha K, Kucharczyk R, Zagożdżon R. The Role of Glomerular and Serum Expression of Lymphocyte Activating Factors BAFF and APRIL in Patient with Membranous and IgA Nephropathies. Archivum Immunologiae et Therapiae Experimentalis. 2025. doi:10.2478/aite-2025-0018
BibTeX
@article{Moszczuk2025,
author = {Moszczuk, Barbara and Mucha, Krzysztof and Kucharczyk, Róża and Zagożdżon, Radosław},
title = {The Role of Glomerular and Serum Expression of Lymphocyte Activating Factors BAFF and APRIL in Patient with Membranous and IgA Nephropathies},
journal = {Archivum Immunologiae et Therapiae Experimentalis},
year = {2025},
doi = {10.2478/aite-2025-0018}
}
EUVIMED